Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Clinical and economic review of erlotinib in non-small-cell lung cancer.

Yeung K, Carlson JJ.

Expert Rev Pharmacoecon Outcomes Res. 2012 Aug;12(4):411-23. doi: 10.1586/erp.12.42. Review.

PMID:
22971028
2.

Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.

Bradbury PA, Tu D, Seymour L, Isogai PK, Zhu L, Ng R, Mittmann N, Tsao MS, Evans WK, Shepherd FA, Leighl NB; NCIC Clinical Trials Group Working Group on Economic Analysis.

J Natl Cancer Inst. 2010 Mar 3;102(5):298-306. doi: 10.1093/jnci/djp518. Epub 2010 Feb 16.

PMID:
20160168
3.

Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence.

Carlson JJ.

Expert Rev Pharmacoecon Outcomes Res. 2009 Oct;9(5):409-16. doi: 10.1586/erp.09.49. Review.

PMID:
19817524
4.

Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.

Ting J, Tien Ho P, Xiang P, Sugay A, Abdel-Sattar M, Wilson L.

Value Health. 2015 Sep;18(6):774-82. doi: 10.1016/j.jval.2015.04.008. Epub 2015 Jun 22.

5.

Gene-guided gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive non-small cell lung cancer: an economic analysis.

Zhu J, Li T, Wang X, Ye M, Cai J, Xu Y, Wu B.

BMC Cancer. 2013 Jan 29;13:39. doi: 10.1186/1471-2407-13-39.

6.

Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3.

Borget I, Cadranel J, Pignon JP, Quoix E, Coudert B, Westeel V, Dansin E, Madelaine J, Madroszyk A, Friard S, Daniel C, Morin F, Chouaid C; ERMETIC Collaborative Group.

Eur Respir J. 2012 Jan;39(1):172-9. doi: 10.1183/09031936.00201210. Epub 2011 Jun 9.

7.

[Financial aspects of targeted therapy of lung cancer as compared to conventional chemotherapy].

Moldvay J.

Magy Onkol. 2007;51(3):191-6. Epub 2007 Oct 7. Hungarian.

8.

Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis.

Cromwell I, van der Hoek K, Malfair Taylor SC, Melosky B, Peacock S.

Lung Cancer. 2012 Jun;76(3):472-7. doi: 10.1016/j.lungcan.2011.12.003. Epub 2012 Jan 9.

PMID:
22226627
9.

Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer.

Lyseng-Williamson KA.

Pharmacoeconomics. 2010;28(1):75-92. doi: 10.2165/10482880-000000000-00000.

PMID:
20014878
10.

The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer.

Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL.

Value Health. 2009 Jan-Feb;12(1):20-7. doi: 10.1111/j.1524-4733.2008.00415.x. Epub 2008 Jul 18.

11.

Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysis.

Bajaj PS, Veenstra DL, Goertz HP, Carlson JJ.

J Med Econ. 2014 Aug;17(8):538-46. doi: 10.3111/13696998.2014.912987. Epub 2014 May 12.

PMID:
24716717
12.

Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer.

Carlson JJ, Wong WB, Veenstra DL, Reyes C.

J Med Econ. 2011;14(2):159-66. doi: 10.3111/13696998.2011.557457. Epub 2011 Feb 2.

PMID:
21288059
13.

Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21.

Clark GM, Zborowski DM, Santabarbara P, Ding K, Whitehead M, Seymour L, Shepherd FA; National Cancer Institute of Canada Clinical Trials Group.

Clin Lung Cancer. 2006 May;7(6):389-94.

PMID:
16800964
14.

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Murphy M, Stordal B.

Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24. Review.

PMID:
21435938
15.

Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer.

Rosell R, Viteri S, Molina MA, Benlloch S, Taron M.

Curr Opin Oncol. 2010 Mar;22(2):112-20. doi: 10.1097/CCO.0b013e32833500d2. Review.

PMID:
19949333
16.

NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer.

Dillon B, Naidoo B, Knight H, Clark P.

Lancet Oncol. 2012 Aug;13(8):764-5. No abstract available.

PMID:
23024988
17.

[Erlotinib in non-small cell lung cancer].

Takeda M, Okamoto I.

Gan To Kagaku Ryoho. 2011 Jun;38(6):896-900. Japanese.

PMID:
21677478
18.
19.

Erlotinib for the treatment of relapsed non-small cell lung cancer.

McLeod C, Bagust A, Boland A, Hockenhull J, Dundar Y, Proudlove C, Davis H, Green J, Macbeth F, Stevenson J, Walley T, Dickson R.

Health Technol Assess. 2009 Jun;13 Suppl 1:41-7. doi: 10.3310/hta13suppl1/07.

20.

A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.

Nuijten MJ, de Castro Carpe├▒o J, Chouaid C, Vergnen├Ęgre A, Grossi F, Bischoff H, Heigener D, Walzer S.

Lung Cancer. 2012 Jun;76(3):465-71. doi: 10.1016/j.lungcan.2011.11.005. Epub 2011 Dec 5.

PMID:
22153602

Supplemental Content

Support Center